203,800 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 203,800 shares of the biotechnology company’s stock, valued at approximately $16,765,000.

A number of other institutional investors also recently added to or reduced their stakes in ARWR. Tsfg LLC acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $25,000. Optiver Holding B.V. raised its holdings in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the topic of several recent analyst reports. B. Riley Financial increased their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Piper Sandler reissued an “overweight” rating and set a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Leerink Partners boosted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research note on Wednesday, June 17th. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, Sanford C. Bernstein increased their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.33.

Insider Buying and Selling

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the transaction, the director owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael S. Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the transaction, the director directly owned 111,459 shares in the company, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $88.59 on Friday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $21.61 and a 1 year high of $95.49. The company has a market capitalization of $12.48 billion, a PE ratio of -39.37 and a beta of 1.27. The company has a fifty day moving average of $83.58 and a two-hundred day moving average of $73.46.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm had revenue of $75.25 million for the quarter, compared to analyst estimates of $44.17 million. During the same quarter last year, the firm posted ($1.26) EPS. The firm’s revenue for the quarter was up 171.0% on a year-over-year basis. As a group, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.51 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.